Samuel Lee

Vincere Biosciences is dedicated to conquering age-related diseases through the development of small molecule therapeutics empowered by a suite of computational tools alongside traditional biology and drug discovery expertise. Our innovative approach focuses on developing small molecules that enhance the removal of damaged mitochondria by modulating mitochondrial quality control mechanisms, such as mitophagy. With the potential to be groundbreaking, these small molecules could become the world's first-ever medicines capable of slowing down or even halting the progression of debilitating conditions like Parkinson's disease and other age-related diseases. By doing so, we aim to transform the lives of hundreds of millions of patients across the globe. We welcome you to follow our page for more content about our company, our dedicated team, and the science that drives what we do.

All Oculii related news can now be found at @Ambarella Inc . Follow us there so you don’t miss any updates: https://www.linkedin.com/company/ambarella Ambarella, Inc., an edge AI semiconductor and software company, acquired Oculii and its AI radar solutions. The Oculii™ adaptive AI software algorithms enable radar perception using current production radar chips to achieve significantly higher (up to 100X) resolution, longer range and greater accuracy. These improvements eliminate the need for specialized high-resolution radar chips, which have significantly higher power consumption and cost than conventional radar solutions. Ambarella’s Oculii AI radar software can be deployed on Ambarella’s CVflow® AI SoCs, operating in conjunction with leading radar RF solutions to increase safety and reliability. Ambarella also offers integrated Oculii AI radar modules that provide drop-in-ready, full-stack radar sensing solutions.

Control of any Gene in any Species or Cell Type Circularis has used the power of circular RNA to develop a novel method to study and regulate gene expression. This technology has enabled increased bio-therapeutic production, improved targeting of gene therapy, and optimized expression in poorly studied organisms. The elegant design and high throughput nature of this technology enables breakthrough solutions without prior knowledge of the regulatory elements or coding sequence.

Songclip is the all-in-one patented music licensing and integration solution for offering music as a feature in dating apps, gaming apps, messaging apps, social platforms, and more. Working in partnership with UMG, UMPG, WMG, Warner Chappell, Kobalt, BMG, and 7,500 other rights owners, Songclip’s distinctive pass-through licensing model helps app companies navigate the complexities of music licensing and streamlines the go-to-market process. Songclip’s plug-and-play API seamlessly integrates into apps and social platforms to facilitate licensing, search, catalog & compliance, royalty payments, reporting, and end-user analytics. Songclip continuously curates a library of over three million music clips through expert human curation and AI. Each music clip is wrapped in many metadata layers enabling an unparalleled search capability that drives unique music experiences across any consumer app or platform. Songclip is a Clipmedia.ai company.

Copy.ai makes AI accessible for all users, regardless of technical know-how. Our GTM AI Platform makes it easy to drive real business value from the latest large language models (LLMs) and help companies navigate their AI transformation journey. We have over 10 million users, the backing of top tier venture capital firms (Sequoia, Craft, Wing, Tokyo Black), and an incredible tailwind of AI momentum and enthusiasm.

Search all your apps. All your tabs. All in one place. Don’t just save time—strategize how you spend it with Dropbox Dash, your AI-powered universal search tool. Keep your key information just a few clicks away, so you can focus less on busywork and more on big ideas.

An alcohol brand designed for the way millennials drink today. Low-ABV, natural ingredients, delivered to your door.

Swift Solar is a U.S. company developing advanced solar technology that outperforms anything on the market today. Swift Solar is a spinout of Stanford, MIT, and the National Renewable Energy Laboratory. The team includes world-leading technologists with deep expertise in perovskite PV science, technology, and manufacturing. Swift Solars technologies range from specialized solar cell architectures to advanced manufacturing techniques.

Blue Water Biotech Inc. (Nasdaq: BWV) is a biopharmaceutical company focused on developing transformational therapies to address significant health challenges globally. The company holds the rights to proprietary technology developed at the University of Oxford, Cincinnati Childrens Hospital Medical Center (CCHMC), and St. Jude Childrens Hospital. The company is developing a universal flu vaccine that will provide protection from all virulent strains in addition to licensing a novel norovirus (NoV) S&P nanoparticle versatile virus-like particle (VLP) vaccine platform from CCHMC to develop vaccines for multiple infectious diseases, including norovirus/rotavirus and malaria, among others. Additionally, Blue Water Vaccines is developing a Streptococcus pneumoniae (pneumococcus) vaccine candidate, designed to specifically prevent the highly infectious middle ear infections, known as Acute Otitis Media (AOM), in children.

Pragma Bio exists to find cures for undruggable immunological disorders. We use real-world data and synthetic biology to map out multi-layered biological signatures associated with clinical outcomes in order to produce natural chemistry with therapeutic potential.

Our mission at Beacons is to simplify the process for all creators. We are building a home online that helps creators build connections with their audiences and provides ease in monetizing their brand all while being given the creative freedom to fully customize their pages. As the world moves online, we believe everyone should have their own website where they can fully express themselves. A website with your own branding and your message, and we strive to provide the building blocks for this new mobile, online world.

Minimally Invasive Technology for Obstructive Sleep Apnea

Standard Bariatrics® is committed to creating superior Bariatric/Metabolic Surgery clinical and economic outcome solutions for Patients and Healthcare Providers. We are leading the charge to harmonize the sleeve gastrectomy procedure with the Titan SGS® Stapling Technology, an anatomy-based approach to sleeve gastrectomy performed laparoscopically. By working alongside bariatric surgeons, we are actively developing a portfolio of medical devices to assist surgeons in shaping the future of Bariatric Surgery.

American Gene Technologies® International Inc. (AGT™) is a private biotechnology company pursuing cures and treatments for infectious diseases, cancers, and monogenic disorders. AGT™s emerging gene and cell therapeutics programs are designed to: ✅ Create immunotherapy for HIV disease with gene-modified T cells ✅ Activate innate T cell immunity capable of killing all tumor cells with its vector used in immuno-oncology ✅ Treat PKU by bringing a functional gene into cells that express a dysfunctional gene due to mutation ✅ Advance clinically to provide human proof of concept For over a decade, AGT™ has developed, tested, and banked thousands of lentiviral vectors that can be adapted to the specific needs of new target diseases. AGT™ has developed gene therapy for diseases using this rapid gene delivery platform. GENE THERAPIES AGT™’s platform allows it to pursue clinical “cures” for complex diseases. The company has developed patent-protected gene therapeutics that are breakthroughs in medicine. *** See our extensive award winning patents on our website *** HIV/AIDS Immunotherapy for HIV disease with gene-modified T cells IMMUNO-ONCOLOGY Activates innate T cell immunity capable of killing all tumor cells with its vector used in immuno-oncology PHENYLKETONURIA (PKU) Treats PKU by bringing a functional gene into cells that express a dysfunctional gene due to mutation AGT™s Core Objectives ✔️ Leverage our lentivirus platform to create highly-effective targeted genetic medicines ✔️ Create solutions for patients across a spectrum of infectious diseases, cancers and inherited disorders ✔️ Collaborate with leading medical researchers from around the globe To learn more and get in touch with American Gene Technologies® Inc., contact us today at https://www.americangene.com/contact-us/

Vincere Biosciences is dedicated to conquering age-related diseases through the development of small molecule therapeutics empowered by a suite of computational tools alongside traditional biology and drug discovery expertise. Our innovative approach focuses on developing small molecules that enhance the removal of damaged mitochondria by modulating mitochondrial quality control mechanisms, such as mitophagy. With the potential to be groundbreaking, these small molecules could become the world's first-ever medicines capable of slowing down or even halting the progression of debilitating conditions like Parkinson's disease and other age-related diseases. By doing so, we aim to transform the lives of hundreds of millions of patients across the globe. We welcome you to follow our page for more content about our company, our dedicated team, and the science that drives what we do.

All Oculii related news can now be found at @Ambarella Inc . Follow us there so you don’t miss any updates: https://www.linkedin.com/company/ambarella Ambarella, Inc., an edge AI semiconductor and software company, acquired Oculii and its AI radar solutions. The Oculii™ adaptive AI software algorithms enable radar perception using current production radar chips to achieve significantly higher (up to 100X) resolution, longer range and greater accuracy. These improvements eliminate the need for specialized high-resolution radar chips, which have significantly higher power consumption and cost than conventional radar solutions. Ambarella’s Oculii AI radar software can be deployed on Ambarella’s CVflow® AI SoCs, operating in conjunction with leading radar RF solutions to increase safety and reliability. Ambarella also offers integrated Oculii AI radar modules that provide drop-in-ready, full-stack radar sensing solutions.

Control of any Gene in any Species or Cell Type Circularis has used the power of circular RNA to develop a novel method to study and regulate gene expression. This technology has enabled increased bio-therapeutic production, improved targeting of gene therapy, and optimized expression in poorly studied organisms. The elegant design and high throughput nature of this technology enables breakthrough solutions without prior knowledge of the regulatory elements or coding sequence.

Songclip is the all-in-one patented music licensing and integration solution for offering music as a feature in dating apps, gaming apps, messaging apps, social platforms, and more. Working in partnership with UMG, UMPG, WMG, Warner Chappell, Kobalt, BMG, and 7,500 other rights owners, Songclip’s distinctive pass-through licensing model helps app companies navigate the complexities of music licensing and streamlines the go-to-market process. Songclip’s plug-and-play API seamlessly integrates into apps and social platforms to facilitate licensing, search, catalog & compliance, royalty payments, reporting, and end-user analytics. Songclip continuously curates a library of over three million music clips through expert human curation and AI. Each music clip is wrapped in many metadata layers enabling an unparalleled search capability that drives unique music experiences across any consumer app or platform. Songclip is a Clipmedia.ai company.